MeDomino CEO Lu Wenqing brought the latest AI tool, ACE, to an industry competition.
The "SaaS Meets Large Model (AI) Innovation Competition," hosted by CuiNiu Club, is an industry event that showcases SaaS product innovation from the technical side. The competition brings together top technical talent in ToB software, uses global frontier technologies, and explores practical scenarios for digital intelligence implementation in Chinese enterprises.
As a digital-intelligence partner for the life sciences industry, AI is one of MeDomino's important capabilities. After more than a month of competition, MeDomino ACE stood out from more than 100 projects, successfully reached the finals, and won an award.
MeDomino CEO Lu Wenqing appeared on the finals stage with ACE
MeDomino ACE, Assistant to Customer Engagement, is an assistant tool created specifically for frontline colleagues in pharma and medtech companies. It includes personalized interpretation of private industry data, personalized talking-point generation, and enterprise knowledge-base Q&A based on RAG, fully matching pharma and medtech business scenarios. First, let us watch a short video to see MeDomino ACE in action:
As shown in the video, MeDomino ACE not only provides frontline teams with individual profile data for the specific customers they are responsible for, but also combines large-model capabilities to generate highly targeted individual communication guidance and content suggestions. It can quickly answer customers' professional clinical questions based on the enterprise knowledge base, helping pharma and medtech companies greatly improve the effectiveness of frontline visits and helping frontline colleagues build touchpoints and trust with every customer.
For example, based on the platform's previous deep customer insights and inventory of enterprise content resources, we can know that a certain customer is suitable for a certain piece of content or meeting. After instructions are sent to frontline colleagues, they can directly view and execute them through ACE.
Currently, MeDomino has established ongoing cooperation with 95% of the world's top 20 pharmaceutical companies, as well as several global leading medical device companies.
In the future, we will continue to stay on the path of digital-intelligent transformation in the life sciences industry, using AI algorithms and big data capabilities to help more client enterprises drive business growth and improve efficiency.
